Lung Cancer Failure Isn't The End For Merck KGaA And GSK's Bintrafusp

But Frontline NSCLC Was Biggest Opportunity

 
• By Andrew McConaghie
  
Merck KGaA Darmstadt
Merck KGaA, Darmstadt: the company is counting on its oncology pipeline to boost revenues to €2bn by 2022. • Source: Getty Images
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip